Amgen Execs to Discuss Strategy at Leerink Healthcare Conference
Event summary
- Amgen CFO Peter Griffith and Rare Disease SVP Jasper van Grunsven to participate in fireside chat on March 11, 2026.
- Webcast available live and archived for 90 days on Amgen's investor relations page.
- Presentation part of broader investor communications strategy around business developments.
- Amgen focuses on pipeline for cancer, inflammatory conditions, rare diseases, heart disease, and obesity.
The big picture
Amgen's participation in the Leerink conference comes as biotech firms face increasing pressure to demonstrate pipeline resilience amid regulatory scrutiny and pricing challenges. The company's focus on rare diseases and obesity aligns with broader industry shifts toward specialized therapeutics. As a Dow Jones and Nasdaq-100 component, Amgen's strategic updates carry weight for both sector investors and broader market indices.
What we're watching
- Pipeline Progress
- How Amgen's updates on cancer and rare disease treatments will impact investor sentiment.
- Financial Strategy
- Whether CFO Griffith will address cost pressures or M&A opportunities in the fireside chat.
- Market Positioning
- The pace at which Amgen can differentiate itself in competitive therapeutic areas.
Related topics